Skip to main content
main-content

Pediatric rheumatology

Comorbidities

19-05-2020 | Kawasaki disease | News

COVID-19 linked to outbreak of severe Kawasaki-like disease

Italian researchers report a 30-fold increase in the incidence of severe Kawasaki-like disease with the emergence of COVID-19.

Read the linked commentary from Sangeeta Sule.

08-04-2020 | COVID-19 | News

ACR advises on resource allocation during COVID-19 pandemic

The ACR has issued guiding principles for the allocation of hydroxychloroquine, IL-1 and 6 antagonists, JAK inhibitors, and eculizumab during the COVID-19 pandemic.

30-03-2020 | Etanercept biosimilar | News

Etanercept biosimilar receives positive CHMP opinion

Click through for more information

27-03-2020 | COVID-19 | Podcast | Audio

COVID-19: A pediatric rheumatologist’s perspective

Sangeeta Sule, from Children’s National Hospital in Washington, DC, USA, shares her experience of how the pediatric rheumatology community is adapting to the COVID-19 pandemic, including the use of telemedicine practices (9:06).

EULAR 2020 E-Congress hub

Access the latest news and expert video commentary from the EULAR 2020 E-Congress.

TB screening important for biologic therapy users

Screening for and treatment of latent tuberculosis infection are important preventive strategies in people receiving biologic therapies for rheumatic diseases, irrespective of the drug class, South African researchers report.

10-12-2019 | Infection | News

TB screening important for biologic therapy users

Screening for and treatment of latent tuberculosis infection are important preventive strategies in people receiving biologic therapies for rheumatic diseases, irrespective of the drug class, South African researchers report.

Etanercept not linked to uveitis risk in real-world JIA study

An analysis of two UK juvenile idiopathic arthritis registries suggests no significant difference in uveitis risk among patients treated with the TNF inhibitor etanercept relative to methotrexate.

22-10-2019 | Juvenile idiopathic arthritis | Highlight | News

Etanercept not linked to uveitis risk in real-world JIA study

An analysis of two UK juvenile idiopathic arthritis registries suggests no significant difference in uveitis risk among patients treated with the TNF inhibitor etanercept relative to methotrexate.

26-06-2019 | Juvenile idiopathic arthritis | News

Anxiety, depressive symptoms linked to pain and disability in JIA

Anxiety and depressive symptoms are associated with pain and disability but not active joint count or biomarkers of inflammation in adolescents with juvenile idiopathic arthritis, researchers report.

17-06-2019 | Juvenile idiopathic arthritis | EULAR 2019 | News

Further investigation of tocilizumab for JIA-associated uveitis may be warranted

Approximately half of the 21 patients with juvenile idiopathic arthritis-associated uveitis in the APTITUDE trial experienced an improvement in uveitis assessment with 12 weeks of tocilizumab treatment.

ACR/National Arthritis Foundation guidelines for managing JIA released

The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.

07-05-2019 | Juvenile idiopathic arthritis | Highlight | News

ACR/National Arthritis Foundation guidelines for managing JIA released

The ACR and the National Arthritis Foundation have published two guidelines on juvenile idiopathic arthritis, one providing recommendations for the treatment of polyarthritis, sacroiliitis, and enthesitis, and the other focusing on detecting and treating uveitis.

11-01-2019 | Juvenile idiopathic arthritis | News

Predictors of outcomes identified in JIA-associated uveitis

Demographic factors, measures of disease activity, and the type of treatment used are associated with 2-year outcomes among patients with juvenile idiopathic arthritis-associated uveitis, according to findings from the ICON-JIA study.

26-11-2018 | Juvenile idiopathic arthritis | News

Disease subtype, treatment choice may impact infection risk in JIA patients

Among biologic-treated patients with juvenile idiopathic arthritis, infection risk may differ according to disease subtype and the biologic agent used, researchers report.

24-10-2018 | Pediatric | ACR/ARHP 2018 | Video

Expert highlights: Sangeeta Sule

Editorial board member Sangeeta Sule discusses her highlights from the pediatric rheumatology sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA (2:14).

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

01-10-2018 | Kawasaki disease | Article

Association of initially normal coronary arteries with normal findings on follow-up echocardiography in patients with Kawasaki disease

de Ferranti SD et al. JAMA Pediatr 2018: e183310. doi: 10.1001/jamapediatrics.2018.3310

Image Credits